Aml Research

What we do

AML Clinical Services provides focused clinical research services to pharmaceutical, medical device and biotechnology companies, contract research organisations (CROs) and research sites.

 A dedicated team of qualified research professionals is available to assist in any stage of the conduct of  clinical trials, in any therapeutic area.  We have experience in pre-marketing as well as late phase and post-marketing trials.

AML retains a small-scaled organization to guarantee close oversight, commitment, loyalty and low turnover. Our employees are valued for their high experience, knowledge, flexibility and dedication to their responsibilities.


Tempelzicht 8

3210 Linden, Belgium

+32(0)16 78 21 70

+32(0)16 78 86 72

connect with us

Mission statement

It is our mission to make each and every clinical trial a success by reducing study start-up time, meeting project timelines and assuring high quality clinical data.

With our CAN DO attitude we turn problems into challenges to manage.  And while doing this, we value team work as well as integrity, open communication and mutual respect.

In the picture: ICH GCP E6 training revised

On December 15, 2016,  the long awaited ICH GCP E6 (R2) Addendum was adopted. It is a response to the increase in scale, complexity, and cost of clinical trials. The EMA welcomed the R2 changes, stating that these new guidelines “will provide increased clarity and encourage implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording, and reporting”. The new ICH GCP E6 (R2) Addendum introduced 26 new items covering three main areas of clinical research: data management, and sponsor and investigator responsibilities.

The fundamental differences between the R1 and R2 version of the guidelines are in respect to sponsor/investigator responsibilities and risk-based monitoring. The new guidelines will come into force on 14 June 2017 and will have a global impact on anyone involved in the clinical research process.

Sponsor and investigators should prepare for the revision coming into effect. We already revised our ICH GCP E6 training to the changes in the addendum R2 to help investigators being prepared.

Check our revised ICH-GCP E6 (R2) training

ICH GCP Training